Ukraine may restrict imports of foreign drugs

4 October 2012

Ukraine may restrict imports of foreign drugs to the country, the quality of which do not comply with international standards, according to the press-service of the Ukrainian government. In addition, according to sources close to the government, this should make drugs more affordable to local population, the purchase power of which remains low, reports The Pharma Letter’s Russian correspondent.

Despite ever growing domestic production, high prices for drugs, so far, remain one of the main problems of the Ukrainian pharmaceutical market. However there is a possibility that this problem may be partly solved in the near future as, prior to the elections in the national parliament, the Ukrainian government has reached an agreement with leading domestic pharmaceutical producers to reduce the prices of their products by at least 12%, promising instead to ban imports of those drugs, which have efficient Ukrainian production. In addition, the Ukrainian government is unhappy with the quality of many drugs, which are currently imported onto the domestic market.

Criticism from global drugmakers

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics